Drug Trial Radar · NCT01274338
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,673
Actual
Start
Jun 17, 2011
Primary completion
Feb 15, 2019
Study completion Feb 2, 2027
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Jan 11, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized phase III trial studies ipilimumab to see how well it works compared to high-dose interferon alfa-2b in treating patients with high-risk stage III-IV melanoma that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Interferon alfa-2b may interfere with the growth of tumor cells and slow the growth of melanoma and other cancers. It is not yet known whether ipilimumab is more effective than interferon alfa-2b in treating patients with melanoma.
Conditions
- Melanoma of Unknown Primary
- Recurrent Melanoma
- Stage IIIB Cutaneous Melanoma AJCC v7
- Stage IIIC Cutaneous Melanoma AJCC v7
- Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions
IpilimumabBiological
Given IV
Quality-of-Life AssessmentOther
Ancillary studies
Recombinant Interferon Alfa-2bBiological
Given IV and SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recurrence-free Survival (RFS; Arm B [HDI] vs. Arm C [LIP])Time frame: Assessed every 3 months for 2 years, then every 6 months for years 3-5 and then annually up to 8 years
- 5-year Overall Survival (OS) Rate (Arm B [HDI] vs. Arm C [LIP])Time frame: Assessed every 3 months for 2 years, then every 6 months for years 3-5
- Recurrence-free Survival (RFS; Arm A [HIP] vs. Arm B [HDI])Time frame: Assessed every 3 months for 2 years, then every 6 months for years 3-5 and then annually up to 8 years
- 5-year Overall Survival (OS) Rate (Arm A [HIP] vs. Arm B [HDI])Time frame: Assessed every 3 months for 2 years, then every 6 months for years 3-5
Locations
937 sites in 2 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama
Providence Hospital
Mobile, Alabama
University of South Alabama Mitchell Cancer Institute
Mobile, Alabama
Alaska Regional Hospital
Anchorage, Alaska
Providence Alaska Medical Center
Anchorage, Alaska
Fairbanks Memorial Hospital
Fairbanks, Alaska
Banner MD Anderson Cancer Center
Gilbert, Arizona
University of Arizona Cancer Center-Orange Grove Campus
Tucson, Arizona
Banner University Medical Center - Tucson
Tucson, Arizona
University of Arizona Cancer Center-North Campus
Tucson, Arizona
Mercy Hospital Fort Smith
Fort Smith, Arkansas
NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
Jonesboro, Arkansas
John L McClellan Memorial Veterans Hospital
Little Rock, Arkansas
University of Arkansas for Medical Sciences
Little Rock, Arkansas
Highlands Oncology Group - Rogers
Rogers, Arkansas
Kaiser Permanente-Deer Valley Medical Center
Antioch, California
PCR Oncology
Arroyo Grande, California
Sutter Auburn Faith Hospital
Auburn, California
Sutter Cancer Centers Radiation Oncology Services-Auburn
Auburn, California
Sutter Cancer Centers Radiation Oncology Services-Cameron Park
Cameron Park, California
Sutter Davis Hospital
Davis, California
Kaiser Permanente-Fremont
Fremont, California
Kaiser Permanente-Fresno
Fresno, California
Saint Jude Medical Center
Fullerton, California
Marin Cancer Care Inc
Greenbrae, California
UC San Diego Moores Cancer Center
La Jolla, California
The Angeles Clinic and Research Institute - West Los Angeles Office
Los Angeles, California
Mattel Children's Hospital UCLA
Los Angeles, California
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California
Memorial Medical Center
Modesto, California
Kaiser Permanente-Modesto
Modesto, California
Community Hospital of Monterey Peninsula
Monterey, California
Palo Alto Medical Foundation-Camino Division
Mountain View, California
Palo Alto Medical Foundation-Gynecologic Oncology
Mountain View, California
Sutter Cancer Research Consortium
Novato, California
Kaiser Permanente-Oakland
Oakland, California
Saint Joseph Hospital - Orange
Orange, California
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California
Palo Alto Medical Foundation Health Care
Palo Alto, California
Stanford Cancer Institute Palo Alto
Palo Alto, California
Showing 40 of 937 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.